| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Nunes, Maria Carmo |
| dc.contributor.author | Bern, Caryn |
| dc.contributor.author | Clark, Eva |
| dc.contributor.author | Teixeira, Antonio Lucio |
| dc.contributor.author | Molina Romero, Israel |
| dc.date.accessioned | 2024-11-26T11:37:20Z |
| dc.date.available | 2024-11-26T11:37:20Z |
| dc.date.issued | 2024-09 |
| dc.identifier.citation | Nunes MCP, Bern C, Clark EH, Teixeira AL, Molina I. Clinical features of Chagas disease progression and severity. Lancet Reg Heal Am. 2024 Sep;37:100832. |
| dc.identifier.issn | 2667-193X |
| dc.identifier.uri | https://hdl.handle.net/11351/12277 |
| dc.description | Chagas cardiomyopathy; Chagas disease; Progression |
| dc.description.abstract | Chagas disease, the most common form of nonischaemic cardiomyopathy globally, is one of the leading causes of morbidity and mortality in Latin America. Chagas cardiomyopathy has a wide clinical spectrum and prognosis, which is primarily determined by the severity of left ventricular dysfunction. Chagas disease also affects the brain, particularly manifesting as cardioembolic strokes and cognitive impairments. Disease progression is influenced by various factors such as anti-parasite treatments, host–parasite interactions, and other determinants.
This review explores Chagas disease, covering clinical presentations, the range of severity of Chagas cardiomyopathy, and neurological manifestations. We investigate factors that influence the progression of cardiomyopathy, including anti-parasitic treatments, interactions between hosts and parasites, and the influence of social determinants on the course of the disease. This review analyses key prognostic factors associated with the progression and mortality of Chagas cardiomyopathy, offering insights into this potentially fatal illness. |
| dc.language.iso | eng |
| dc.publisher | Elsevier |
| dc.relation.ispartofseries | The Lancet Regional Health Americas;37 |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Chagas, Malaltia de - Prognosi |
| dc.subject | Miocardi - Malalties - Prognosi |
| dc.subject.mesh | Chagas Cardiomyopathy |
| dc.subject.mesh | Chagas Disease |
| dc.subject.mesh | Disease Progression |
| dc.title | Clinical features of Chagas disease progression and severity |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1016/j.lana.2024.100832 |
| dc.subject.decs | miocardiopatía chagásica |
| dc.subject.decs | enfermedad de Chagas |
| dc.subject.decs | progresión de la enfermedad |
| dc.relation.publishversion | https://doi.org/10.1016/j.lana.2024.100832 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Nunes MCP] Hospital das Clínicas and Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. [Bern C] Department of Epidemiology and Biostatistics, University of California San Francisco School of Medicine, San Francisco, CA, USA. [Clark EH] Department of Medicine, Section of Infectious Diseases and Department of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA. [Teixeira AL] Faculdade Santa Casa BH, Belo Horizonte, MG, Brazil. The Biggs Institute, UT Health Science Center, San Antonio, TX, USA. [Molina I] Unitat de Medicina Tropical i Salut Internacional Drassanes, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
| dc.identifier.pmid | 39474468 |
| dc.identifier.wos | 001316791500001 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |